Share This Page
Drug Price Trends for NDC 59651-0063
✉ Email this page to a colleague
Average Pharmacy Cost for 59651-0063
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DUTASTERIDE-TAMSULOSIN 0.5-0.4 | 59651-0063-30 | 2.01940 | EACH | 2026-03-18 |
| DUTASTERIDE-TAMSULOSIN 0.5-0.4 | 59651-0063-90 | 2.01940 | EACH | 2026-03-18 |
| DUTASTERIDE-TAMSULOSIN 0.5-0.4 | 59651-0063-30 | 2.22592 | EACH | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 59651-0063
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Lexapro (Escitalopram) Market Analysis and Price Projections
Overview
The Lexapro (escitalopram) market is characterized by a mature, genericized landscape with ongoing price erosion driven by multiple generic manufacturers. While originator brand Lexapro sales have declined significantly post-patent expiry, the active pharmaceutical ingredient (API), escitalopram, continues to represent a substantial volume in the antidepressant market. Key market drivers include the prevalence of anxiety and depression disorders, the drug's established efficacy and safety profile, and competitive pricing among generic suppliers. Price projections indicate continued downward pressure, with potential stabilization occurring as the market consolidates.
What is the Current Market Size and Segmentation for Escitalopram?
The global market for escitalopram, primarily driven by generic sales following the patent expiry of branded Lexapro, is substantial and segmented by formulation, indication, and distribution channel. Precise, real-time market size figures fluctuate due to the highly competitive generic environment. However, industry reports indicate the antidepressant market, which escitalopram significantly contributes to, is valued in the tens of billions of dollars globally.
Escitalopram is primarily indicated for the treatment of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). These two indications account for the vast majority of its therapeutic use.
Segmentation Breakdown:
- By Formulation:
- Tablets
- Oral Solution
- By Indication:
- Major Depressive Disorder (MDD)
- Generalized Anxiety Disorder (GAD)
- Other psychiatric disorders (e.g., social anxiety disorder, panic disorder - less common primary indications for escitalopram compared to MDD and GAD)
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Government and Public Sector
- By Region:
- North America (U.S., Canada)
- Europe (Germany, UK, France, Italy, Spain, Rest of Europe)
- Asia Pacific (China, Japan, India, Rest of Asia Pacific)
- Latin America
- Middle East and Africa
The U.S. market, being the largest pharmaceutical market, represents a significant portion of global escitalopram consumption. The increasing prevalence of mental health disorders and growing awareness contribute to sustained demand across all major geographic regions.
What is the Competitive Landscape for Escitalopram?
The competitive landscape for escitalopram is dominated by generic manufacturers following the patent expiry of branded Lexapro (escitalopram oxalate), originally marketed by Lundbeck and Forest Laboratories. The U.S. patent for Lexapro expired in 2012 [1]. This event triggered the entry of numerous generic players, leading to intense price competition.
Key characteristics of the competitive landscape include:
- High Number of Generic Manufacturers: Over a dozen manufacturers and suppliers offer escitalopram products in the U.S. alone. This widespread availability fosters a highly competitive market.
- Price Erosion: The primary consequence of numerous generic entrants is significant and continuous price erosion. Generic drug prices typically fall by 50-80% within the first year of a second generic entering the market [2]. For escitalopram, this trend has been ongoing for over a decade.
- Major Generic Players (Examples): While specific market share data for individual generic escitalopram manufacturers is often proprietary and fluctuates, key players in the U.S. generic market include companies such as:
- Teva Pharmaceuticals
- Mylan (now part of Viatris)
- Sun Pharmaceutical Industries
- Apotex
- Cipla
- Lupin
- Amneal Pharmaceuticals
- Supply Chain Dynamics: The availability of escitalopram API from various global suppliers (particularly from India and China) also influences pricing and supply chain stability.
- Market Access and Reimbursement: Payer formularies and preferred drug lists play a crucial role in market access for escitalopram. Generic escitalopram is widely covered by most insurance plans and government programs due to its cost-effectiveness.
- Product Differentiation (Limited): For generic escitalopram, differentiation is minimal, primarily focusing on tablet count, packaging, and, to a lesser extent, formulation (e.g., immediate-release tablets vs. oral solution). Brand loyalty is negligible in the generic segment.
The intense competition has shifted the focus from innovation to cost-efficient manufacturing and distribution. Manufacturers compete on price, volume, and reliability of supply.
What are the Historical Price Trends for Escitalopram?
The historical price trends for escitalopram demonstrate a dramatic decline from the originator brand's peak pricing to the current generic market values.
Key historical price trends:
- Pre-Generic Era (Branded Lexapro): Branded Lexapro commanded premium pricing. For example, in the early 2010s, a 30-day supply of 10mg Lexapro could cost upwards of \$150-\$200 or more, depending on the pharmacy and insurance coverage [3].
- Post-Patent Expiry (2012 onwards):
- Initial Generic Entry: Upon the entry of the first generic escitalopram in 2012, prices began to decrease.
- Rapid Decline with Multi-Generic Competition: As more manufacturers entered the market, prices experienced a sharp and sustained decline. Within a few years of multiple generic competitors, the average wholesale price (AWP) or average manufacturer price (AMP) for a 30-day supply of generic escitalopram dropped to under \$50.
- Continued Erosion: The trend of price erosion has persisted for over a decade. Prices for a 30-day supply of generic escitalopram (e.g., 10mg tablets, 30-day count) have fallen to ranges between \$5 and \$20 for cash-paying customers, and even lower for institutional contracts and large purchasers. This represents a reduction of over 90% from the peak branded price.
- Factors Influencing Historical Prices:
- Exclusivity Period: The period of single-source or limited generic competition.
- Number of Generic Entrants: More competitors lead to steeper price drops.
- API Cost: Fluctuations in the cost of escitalopram API.
- Manufacturing Efficiency: Improvements in production processes by generic companies.
- Wholesaler and Pharmacy Markups: While declining, these still contribute to the final consumer price.
The pricing model for generic drugs is largely driven by volume and cost of goods sold. The market has reached a point where escitalopram is one of the most cost-effective SSRI options available.
What are the Current Pricing Structures and Average Selling Prices (ASPs) for Escitalopram?
The current pricing of escitalopram is predominantly dictated by the generic market dynamics, leading to highly competitive Average Selling Prices (ASPs). These prices vary based on the volume purchased, the specific dosage strength, the count per bottle, the supplier, and the channel (e.g., retail, institutional, online).
Typical Pricing Structures:
- Per-Tablet Pricing: For large institutional contracts or bulk purchases, pricing is often negotiated on a per-tablet basis.
- Per-Bottle/Per-Prescription Pricing: This is more common for retail pharmacy and direct-to-consumer sales. Prices are quoted for a standard prescription quantity, usually a 30-day or 90-day supply.
- Wholesale Acquisition Cost (WAC): This is the list price of a drug. Generic WACs are significantly lower than branded WACs.
- Average Wholesale Price (AWP): This is a benchmark price used by payers, representing the average price of a drug reported by wholesalers.
- Average Manufacturer Price (AMP): This is the average price paid to the manufacturer by wholesalers or directly by retailers or other purchasers. AMP is a key metric for Medicaid reimbursement.
- Net Price: The actual price paid after rebates, discounts, and other concessions. This is often proprietary.
Estimated Current Average Selling Prices (ASPs) for a 30-day supply (e.g., 10mg tablets, 30 count):
- Cash-Paying Customers (Retail Pharmacy): \$5 - \$20. Prices can be as low as \$5 if using discount cards or pharmacy savings programs.
- PBM/Insured Patients (Copay): Copays typically range from \$0 to \$10, depending on the insurance plan's tiering and formulary placement for generics. The net cost to the insurer is significantly lower.
- Institutional Contracts (Hospitals, Long-Term Care Facilities): Prices are negotiated at much lower rates, often below \$5 per 30-day supply, sometimes in the range of \$1 - \$3 per 30-day supply, especially for high-volume contracts.
- Online Pharmacies/Discount Programs: May offer pricing comparable to or slightly below the lower end of retail cash prices.
Factors influencing current ASPs:
- Volume: Higher purchase volumes secure lower per-unit pricing.
- Competition: The presence of multiple suppliers in any given market segment.
- API Sourcing: Cost-effective procurement of escitalopram API.
- Manufacturing Location and Costs: Labor, regulatory compliance, and overhead expenses.
- Distribution Efficiency: Logistics and supply chain management.
- Payer Negotiations: Strength of pharmacy benefit managers (PBMs) and other payers in negotiating discounts.
The ASP for generic escitalopram has largely stabilized at very low levels, reflecting the mature stage of its lifecycle.
What are the Regulatory and Patent Statuses Affecting Escitalopram?
The regulatory and patent landscape for escitalopram has been the primary driver of its market evolution from a high-priced branded drug to a widely accessible generic.
Patent Status:
- Orphaned Patents: The primary patents protecting branded Lexapro (escitalopram oxalate) expired in the United States in 2012. Secondary patents related to specific formulations or methods of use may have had staggered expiration dates, but these did not prevent broad generic entry following the expiry of the core composition-of-matter patents [1].
- Generic Drug Approvals: The U.S. Food and Drug Administration (FDA) has approved numerous Abbreviated New Drug Applications (ANDAs) for generic escitalopram products from various manufacturers. This signifies that these generic versions are bioequivalent to the branded product.
- Exclusivity: Any remaining market exclusivity for branded Lexapro expired long ago. Generic manufacturers now compete without significant patent-related barriers.
Regulatory Status:
- FDA Approval: All generic escitalopram products marketed in the U.S. are approved by the FDA, meaning they meet stringent standards for safety, efficacy, and manufacturing quality.
- Good Manufacturing Practices (GMP): Manufacturers are required to adhere to FDA's GMP regulations, ensuring consistent product quality.
- Labeling Requirements: Generic drug labeling must be essentially the same as the branded drug's labeling, with permissible differences in inactive ingredients.
- Pharmacovigilance: All manufacturers are subject to post-market surveillance and adverse event reporting requirements.
- International Regulations: Similar patent expiries and generic approval processes have occurred in other major markets (e.g., Europe, Canada, Australia), following the regulatory pathways of their respective health authorities (e.g., European Medicines Agency).
The regulatory framework, particularly the FDA's ANDA pathway, is designed to facilitate the rapid and cost-effective introduction of generic drugs once patents expire, directly leading to the current competitive pricing of escitalopram.
What are the Future Price Projections for Escitalopram?
Future price projections for escitalopram indicate continued stability at low levels, with potential for marginal fluctuations rather than significant increases or decreases. The market has reached a mature stage characterized by intense competition and optimized manufacturing costs.
Key Projection Factors:
- Sustained Competition: The existing large number of generic manufacturers is unlikely to significantly diminish in the short to medium term. This ensures continued competitive pricing pressures.
- Stable API Costs: While API costs can fluctuate based on global supply, demand, and geopolitical factors, the escitalopram API market is well-established, suggesting relatively stable input costs for most manufacturers.
- Manufacturing Efficiencies: Manufacturers have already optimized their production processes to achieve low costs. Further significant cost reductions are unlikely without major technological advancements in synthesis.
- Demand Stability: The demand for escitalopram, driven by the prevalence of depression and anxiety, is expected to remain robust. However, the market is unlikely to see significant demand growth beyond population increases and general awareness of mental health.
- Payer Influence: Pharmacy benefit managers (PBMs) and other large payers will continue to exert pressure for the lowest possible prices through contract negotiations and formulary management.
- Consolidation: While not guaranteed, some degree of industry consolidation among generic manufacturers could potentially lead to slightly less aggressive price competition in specific segments over the longer term, but the overall price trajectory is unlikely to reverse.
- New Entrants (Unlikely): Given the low margins and mature market, the likelihood of significant new, large-scale entrants is low, unless there are unforeseen supply chain disruptions or specific niche opportunities.
Price Projection Summary:
- Short-to-Medium Term (1-3 years): Expect prices to remain within the current range of \$5 - \$20 for a 30-day supply for cash-paying customers. Institutional prices will likely remain below \$5 per 30-day supply. Minor price variations may occur due to promotional activities or temporary supply shortages.
- Long-Term (3-5+ years): The market is expected to exhibit price stability. Significant price increases are highly improbable unless there are widespread API supply disruptions or major shifts in regulatory policy. Any significant price decreases would likely only result from further consolidation leading to reduced competition or drastic reductions in API costs, neither of which is currently anticipated.
The market for generic escitalopram has achieved a state of equilibrium where pricing is dictated by efficient, large-scale production and intense competition, rather than innovation or market exclusivity.
Key Takeaways
- The global market for escitalopram is mature and dominated by generic competition following the patent expiry of branded Lexapro in 2012.
- Intense price erosion has occurred over the past decade, with 30-day supplies now available for as low as \$5-\$20 for cash-paying consumers, and significantly less for institutional buyers.
- Key market drivers include the persistent prevalence of depression and anxiety disorders and the drug's established therapeutic profile.
- Numerous generic manufacturers, including Teva, Mylan (Viatris), and Sun Pharma, compete primarily on price and supply chain reliability.
- Future price projections indicate continued stability at current low levels, with minimal expected price increases or significant decreases. The market is unlikely to experience substantial shifts beyond minor fluctuations driven by competitive pressures and payer negotiations.
Frequently Asked Questions
-
When did the patent for branded Lexapro expire in the U.S.? The primary composition-of-matter patent for branded Lexapro (escitalopram oxalate) expired in the United States in 2012 [1].
-
What is the typical dosage of escitalopram prescribed? Common prescribed dosages for escitalopram range from 5 mg to 20 mg per day, depending on the patient's condition and response [4].
-
Can generic escitalopram be considered therapeutically equivalent to branded Lexapro? Yes, generic escitalopram products approved by the FDA are considered bioequivalent to branded Lexapro, meaning they are expected to have the same safety and efficacy profiles when used as prescribed [5].
-
What is the primary reason for the low price of generic escitalopram? The primary reason for the low price is the intense competition among numerous generic manufacturers following the expiry of the originator's patents, coupled with efficient manufacturing processes and global API sourcing [2].
-
Are there any new indications being explored for escitalopram that could impact its future market? While escitalopram is well-established for MDD and GAD, ongoing research may explore its efficacy in other psychiatric or neurological conditions, but these are unlikely to significantly alter the pricing dynamics of its existing, genericized market in the short to medium term.
Citations
[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book database] (Note: Specific patent expiry dates are often dynamic and best referenced through the FDA's official Orange Book or patent litigation databases.)
[2] Generic Pharmaceutical Association. (n.d.). The Value of Generics. Retrieved from [GPhA website] (Note: GPhA is now a part of PhRMA, and specific historical reports might be archived.)
[3] GoodRx. (n.d.). Lexapro Prices, Coupons, and Patient Assistance Programs. Retrieved from [GoodRx website] (Note: Historical pricing data available through prescription price comparison websites.)
[4] National Institutes of Health. (n.d.). Escitalopram. National Library of Medicine. Retrieved from [MedlinePlus website]
[5] U.S. Food & Drug Administration. (2020). About Generic Drugs. Retrieved from [FDA generic drugs webpage]
More… ↓
